Knight Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Knight Therapeutics has a total shareholder equity of CA$773.9M and total debt of CA$51.7M, which brings its debt-to-equity ratio to 6.7%. Its total assets and total liabilities are CA$962.3M and CA$188.4M respectively. Knight Therapeutics's EBIT is CA$10.3M making its interest coverage ratio 277.7. It has cash and short-term investments of CA$172.3M.
Key information
6.7%
Debt to equity ratio
CA$51.65m
Debt
| Interest coverage ratio | 277.7x |
| Cash | CA$172.32m |
| Equity | CA$773.91m |
| Total liabilities | CA$188.39m |
| Total assets | CA$962.29m |
Recent financial health updates
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03
Recent updates
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 09Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 28Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why
May 07Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Apr 07Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares
Mar 20If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%
Mar 02Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 03Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?
Jan 19What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?
Jan 04A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
Dec 20The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares
Dec 07Financial Position Analysis
Short Term Liabilities: GUD's short term assets (CA$397.6M) exceed its short term liabilities (CA$118.2M).
Long Term Liabilities: GUD's short term assets (CA$397.6M) exceed its long term liabilities (CA$70.2M).
Debt to Equity History and Analysis
Debt Level: GUD has more cash than its total debt.
Reducing Debt: GUD's debt to equity ratio has increased from 0% to 6.7% over the past 5 years.
Debt Coverage: GUD's debt is well covered by operating cash flow (102.1%).
Interest Coverage: GUD's interest payments on its debt are well covered by EBIT (277.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:24 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Knight Therapeutics Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |